Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Uterine Neoplasms Uterine Cervical Neoplasms Biliary Tract Neoplasms Urologic Neoplasms Carcinoma, Non-Small-Cell Lung Breast Neoplasms Cervical cancer Uterine cancer Biliary tract cancer Urothelial cancer Non-squamous non-small cell lung cancer Non-squamous NSCLC Breast cancer Colorectal cancer Ampullary cancer Solid tumors Solid tumors harboring somatic HER2 mutations Seattle Genetics Neoplasms Trastuzumab Fulvestrant Tucatinib Tucatinib + Trastuzumab (+ Fulvestrant)
Lead Scientist at University of California Health
- Rana R McKay (ucsd)
Associate Clinical Professor, Medicine. Authored (or co-authored) 141 research publications.
- accepting new patients
- Start Date
- Completion Date
- Seagen Inc.
- Phase 2
- Study Type
- Last Updated